Skip to content

JBIO JBIO Accounts Payable

Accounts Payable at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$489.3M+10.0%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$12.91M-16.0%
Vera Therapeutics logo
Vera TherapeuticsVERA
$13.91M+50.2%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$7.52M+22.8%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$356K-47.7%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$2.51M-26.2%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's accounts payable?
JBIO (JBIO) reported accounts payable of $3.98M in Q1 2026.
How has JBIO's accounts payable changed year-over-year?
JBIO's accounts payable increased by 5666.7% year-over-year, from $69K to $3.98M.
What is the long-term trend for JBIO's accounts payable?
Over 5 years (2020 to 2025), JBIO's accounts payable has grown at a 28.3% compound annual growth rate (CAGR), from $618K to $2.15M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.